ELR-CXC chemokine antagonism and cisplatin co-treatment additively reduce H22 hepatoma tumor progression and
ameliorate cisplatin-induced nephrotoxicity

Wei,Jing; Chen,Xiangyu; Li,Qiang; Chen,Jifei; Khan,Noman; Wang,Bing; Cheng,Jya-Wei; Gordon,John R.; Li,Fang

doi:10.3892/or.2014.2996

ELR-CXC chemokine antagonism and cisplatin co-treatment additively reduce H22 hepatoma tumor progression and ameliorate cisplatin-induced nephrotoxicity

Authors:
- Jing Wei
- Xiangyu Chen
- Qiang Li
- Jifei Chen
- Noman Khan
- Bing Wang
- Jya-Wei Cheng
- John R. Gordon
- Fang Li
View Affiliations

Affiliations: Department of Immunology, Dalian Medical University, Dalian 116044, P.R. China, Jilin Medical College, Jilin 132013, P.R. China, Institute of Biotechnology, Department of Life Science, National Tsing Hua University, Hsinchu 300, Taiwan, R.O.C., Division of Respirology, Critical Care and Sleep Medicine, Royal University Hospital, University of Saskatchewan, Saskatoon, SK S7N 0W8, Canada
Published online on: January 24, 2014 https://doi.org/10.3892/or.2014.2996
Pages: 1599-1604

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cisplatin (cis-diamminedichloroplatinum) is one of the most commonly used agents for the chemotherapy of various types of cancers, but its use is limited by its dose-dependent side-effects (e.g., nephrotoxicity). The ELR-CXC chemokines are potent tumor growth, metastatic and angiogenic factors and can foster tumor resistance to chemotherapeutic agents. They are also potent proinflammatory agents. The aim of the present study was to evaluate the added effects of combining cisplatin chemotherapy with ELR-CXC chemokine antagonism in a mouse H22 hepatoma cancer cell model. The mice were injected with tumor cells and were then treated with cisplatin (12.5 or 2 mg/kg doses), either alone or together with the chemokine antagonist CXCL8(3-72)K11R/G31P (G31P) (50 µg/kg). At varying time-points renal function was examined using blood urea nitrogen (BUN) and serum creatinine (SCr) as read-outs for the toxic effects of cisplatin, while tumor growth and metastasis were assessed as endpoints. High-dose cisplatin therapy reduced the tumor burden by 52%, while co-delivery of G31P further augmented the tumor growth-suppressive effects of this dose of cisplatin to 71%; G31P by itself and low-dose cisplatin reduced the tumor burden by 19 and 39%, respectively. G31P also reduced the nephrotoxic effects of high-dose cisplatin to the effects observed in the low-dose cisplatin-treated animals. These data confirm the beneficial effects of combined cisplatin chemotherapy and ELR-CXC chemokine anatagonism in the context of both tumor progression and adverse side-effects.

View Figures

View References

1	Zernecke A, Weber KSC, Erwig LP, Kluth DC, Schroppel B, Rees AJ and Weber C: Combinatorial model of chemokine involvement in glomerular monocyte recruitment: role of CXC chemokine receptor 2 in infiltration during nephrotoxic nephritis. J Immunol. 166:5755–5562. 2001. View Article : Google Scholar
2	Miller RP, Tadagavadi RK, Ramesh G and Reeves WB: Mechanisms of cisplatin nephrotoxicity. Toxins. 2:2490–2518. 2010. View Article : Google Scholar
3	Eliopoulos N, Zhao J, Bouchentouf M, Forner K, Birman E, Yuan S, Boivin MN and Martineau D: Human marrow-derived mesenchymal stromal cells decrease cisplatin renotoxicity in vitro and in vivo and enhance survival of mice post-intraperitoneal injection. Am J Physiol Renal Physiol. 299:F1288–F1298. 2010. View Article : Google Scholar
4	Fram RJ: Cisplatin and platinum analogues: recent advances. Curr Opin Oncol. 4:1073–1079. 1992. View Article : Google Scholar : PubMed/NCBI
5	Gonçalves GM, Zamboni DS and Câmara NO: The role of innate immunity in septic acute kidney injuries. Shock. 34(Suppl 1): 22–26. 2010.
6	Matsushima H, Yonemura K, Ohishi K and Hishida A: The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J Lab Clin Med. 131:518–526. 1998. View Article : Google Scholar : PubMed/NCBI
7	Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA and Edelstein CL: Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1β, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther. 322:8–15. 2007.
8	Mukaida N: Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol. 284:L566–L577. 2003. View Article : Google Scholar : PubMed/NCBI
9	Li F, Zhang X and Gordon JR: CXCL8_(3–73)K11R/G31P antagonizes ligand binding to the neutrophil CXCR1 and CXCR2 receptors and cellular responses to CXCL8/IL-8. Biochem Biophys Res Commun. 293:939–944. 2002.
10	Li F, Zhang X, Mizzi C and Gordon JR: CXCL8_(3–73)K11R/G31P antagonizes the neutrophil chemoattractants present in pasteurellosis and mastitis lesions and abrogates neutrophil influx into intradermal endotoxin challenge sites in vivo. Vet Immunol Immunopathol. 90:65–77. 2002.
11	Zhao X, Li F, Town JR, Zhang X, Wang W and Gordon JR: Humanized forms of the CXCR1/CXCR2 antagonist, bovine CXCL8_(3–74)K11R/G31P, effectively block ELR-CXC chemokine activity and airway endotoxemia pathology. Int Immunopharmacol. 7:1723–1731. 2007. View Article : Google Scholar : PubMed/NCBI
12	Zhao X, Town JR, Li F, Zhang X, Cockcroft DW and Gordon JR: ELR-CXC chemokine receptor antagonism targets inflammatory responses at multiple levels. J Immunol. 182:3213–3222. 2009. View Article : Google Scholar : PubMed/NCBI
13	Gordon JR, Li F, Zhang X, Wang W, Zhao X and Nayyar A: The combined CXCR1/CXCR2 antagonist CXCL8_(3–74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals. J Leukoc Biol. 78:1265–1272. 2005.PubMed/NCBI
14	Zhao X, Town JR, Li F, Li W, Zhang X and Gordon JR: Blockade of neutrophil responses in aspiration pneumonia via ELR-CXC chemokine antagonism does not predispose to airway bacterial outgrowth. Pulm Pharmacol Ther. 23:22–28. 2010. View Article : Google Scholar : PubMed/NCBI
15	Zhao X, Town JR, Yang A, Zhang X, Paur N, Sawicki G and Gordon JR: A novel ELR-CXC chemokine antagonist reduces intestinal ischemia reperfusion-induced mortality, and local and remote organ injury. J Surg Res. 162:264–273. 2010. View Article : Google Scholar : PubMed/NCBI
16	Waugh DJ and Wilson C: The interleukin-8 pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
17	Liu X, Peng J, Sun W, Yang S, Deng G, Li F, Cheng JW and Gordon JR: G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice. Tohoku J Exp Med. 228:147–156. 2012. View Article : Google Scholar : PubMed/NCBI
18	Wilson C, Purcell C, Seaton A, Oladipo O, Maxwell PJ, O’Sullivan JM, Wilson RH, Johnston PG and Waugh DJ: Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. J Pharmacol Exp Ther. 327:746–759. 2008. View Article : Google Scholar
19	Wilson C, Wilson T, Johnston PG, Longley DB and Waugh DJ: Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther. 7:2649–2661. 2008. View Article : Google Scholar
20	Kim YS, Moon JI, Kim DK, Kim SI and Park K: Ratio of donor kidney weight to recipient bodyweight as an index of graft function. Lancet. 357:1180–1181. 2001. View Article : Google Scholar : PubMed/NCBI
21	Jüttner S, Wissmann C, Jons T, Vieth M, Hertel J, Gretschel S, Schlag PM, Kemmner W and Hocker M: Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol. 24:228–240. 2006.PubMed/NCBI
22	Moldobaeva A, Baek A, Eldridge L and Wagner EM: Differential activity of pro-angiogenic CXC chemokines. Microvasc Res. 80:18–22. 2010. View Article : Google Scholar : PubMed/NCBI
23	Katyal S, Oliver JH III, Peterson MS, Ferris JV, Carr BS and Baron RL: Extrahepatic metastases of hepatocellular carcinoma. Radiology. 216:698–703. 2000. View Article : Google Scholar : PubMed/NCBI
24	Siddik and Zahid H: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI